Does Vortioxetine Cause Sedation?
Vortioxetine has a low risk of causing sedation and is generally considered to have minimal sedating effects compared to many other antidepressants.
Evidence from FDA Drug Label
According to the FDA-approved prescribing information for vortioxetine (TRINTELLIX), somnolence (drowsiness/sedation) can occur but is not among the most common side effects 1. The drug label specifically notes that vortioxetine has a "low risk of causing sedation" when compared to other antidepressant options 1.
In clinical pharmacology studies, vortioxetine did not impair driving performance or have adverse psychomotor or cognitive effects following single and multiple doses of 10 mg/day in healthy subjects 1. This is particularly important because sedating medications typically impair these functions.
When overdoses up to 80 mg were reported (four times the maximum recommended daily dose), somnolence was noted among the symptoms, but this was in the context of significant overdose rather than therapeutic dosing 1.
Supporting Research Evidence
Multiple research studies corroborate the low sedation profile:
A comprehensive review of vortioxetine's preclinical and clinical data noted "low incidence of sexual dysfunction and sleep disruption" and did not highlight sedation as a prominent adverse effect 2.
A 2015 review specifically stated there is "low risk of weight gain and sedation" with vortioxetine 3.
In a large European post-authorization safety study of 10,358 patients newly prescribed vortioxetine in real-world settings, sedation was not identified as a significant safety concern 4.
A recent systematic review and meta-analysis found vortioxetine was well tolerated with relatively low occurrence of severe treatment-emergent adverse events, with nausea being the most common side effect rather than sedation 5.
In a study of SSRI-resistant OCD patients treated with vortioxetine, sedation occurred in only 18.8% of patients, which was less common than nausea (29.7%) 6.
Clinical Context
The most common side effects of vortioxetine are gastrointestinal symptoms (nausea, constipation, vomiting) rather than sedation 1, 3, 2. This distinguishes it from sedating antidepressants like mirtazapine, trazodone, or certain tricyclic antidepressants, which are specifically used for their sedating properties in guidelines for managing insomnia 7, 8.
Important Caveats:
- Individual variation exists: While sedation risk is low overall, some patients may experience somnolence, particularly during dose initiation or adjustment
- Dose-dependent effects: Higher doses (20 mg) may have slightly different tolerability profiles than lower doses (5-10 mg)
- Drug interactions: Combining vortioxetine with other CNS depressants could theoretically increase sedation risk, though this is not specifically highlighted in the literature
In summary, vortioxetine is among the antidepressants with the lowest propensity to cause sedation, making it a suitable choice when avoiding sedating effects is clinically important.